Q-omics provides the consensus-scored TTLL6 profile across patient tissues and cancer cell-line models. TTLL6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TTLL6 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, TTLL6 RNA expression shows 12,875 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, COAD, and ESCA as cancer lineages where TTLL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL6 survival associations across molecular data types. TTLL6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL6 RNA expression–survival associations across cancer types. High TTLL6 expression shows unfavorable associations in KIRP, DLBC, LUSC, THYM and ESCA, but favorable associations in PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TTLL6 RNA expression.
This table summarizes TTLL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TTLL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL6 shows lower tumor expression in COAD, THCA, LUSC and READ and higher tumor expression in KIRC and STAD. The COAD box plot shows higher TTLL6 RNA expression in normal versus tumor tissue (log2 FC = −2.200, t-test p < 0.001).
This table shows molecular features associated with TTLL6 in patient tissues and cancer cell lines. In patient samples, TTLL6 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
